Angelo Sambunaris is a Psychiatry physician affiliated with Mercer University Health Sciences Center. OpenAlex indexes 17 publications with 542 citations (h-index 11); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5755 N Point Pkwy Ste 256
Alpharetta, GA 300221174
Telephone
770-817-9200Provider last certified this registry record 24 Aug 2023.
Clinical trials
- A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia
Sponsor: Institute for Advanced Medical Research, Alpharetta, GA
- Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
Sponsor: CeNeRx BioPharma Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Pharmaceuticals, IncProgram year20252 payments
- Almatica Pharma LLCProgram year20255 payments
- Axsome Therapeutics, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Benzodiazepine52%Lorazepam83%Alprazolam17%Part D<11 patientsSNRI12.8%Duloxetine Hcl100%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder
International Clinical Psychopharmacology
2016 - Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments
International Clinical Psychopharmacology
2016 - Vilazodone in patients with generalized anxiety disorder
International Clinical Psychopharmacology
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”